- ------------------------------------------------------------------------------------------------------------------------------------ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q - ------------------------------------------------------------------------------------------------------------------------------------ {X} QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2001 Commission File No. 0-19131 MedImmune, Inc. (Exact name of registrant as specified in its charter) Delaware 52-1555759 (State or other jurisdiction of (I. R. S. Employer incorporation or organization) Identification No.) 35 West Watkins Mill Road, Gaithersburg, MD 20878 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (301) 417-0770 Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] As of June 30, 2001, 213,733,442 shares of Common Stock, par value $0.01 per share, were outstanding.EXPLANATORY NOTE This quarterly report on Form 10-Q/A for the quarterly period ended June 30, 2001 is being filed solely to amend the list of exhibits included in Item 6 therein and to re-file a new version of Exhibit 10.128. Exhibit 10.128 was previously and is hereby filed pursuant to a confidential treatment request filed with the Securities and Exchange Commission. The Form 10-Q/A constitutes Amendment No. 1 to MedImmune, Inc.'s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2001. MEDIMMUNE, INC. PART II OTHER INFORMATION Item 6. Exhibits and Reports on Form 8-K (a) Exhibits: 10.128 Supply Transfer Agreement between Immunex Corporation and MedImmune, Inc.* (b) Reports on Form 8-K: Report Date Event Reported ----------- -------------- 5/22/01 Letter to MedImmune Stockholders * Confidential treatment has been requested. The copy filed as an exhibit omits the information subject to the confidentiality request. Such information has been filed separately with the Securities and Exchange Commission. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MEDIMMUNE, INC. (Registrant) /s/: Gregory S. Patrick Date: December 14, 2001 Gregory S. Patrick Senior Vice President and Chief Financial Officer
- MEDI Dashboard
- Filings
- Patents
-
10-Q/A Filing
Medimmune (MEDI) Inactive 10-Q/A2001 Q2 Quarterly report (amended)
Filed: 14 Dec 01, 12:00am